Bank of America Corp DE Has $696,000 Stock Holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Bank of America Corp DE lowered its stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 64.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 149,697 shares of the company's stock after selling 269,320 shares during the period. Bank of America Corp DE's holdings in GoodRx were worth $696,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the company. BNP Paribas Financial Markets purchased a new position in GoodRx in the fourth quarter valued at $183,000. PDT Partners LLC acquired a new stake in GoodRx during the 4th quarter worth $119,000. Northern Trust Corp increased its position in shares of GoodRx by 13.5% during the fourth quarter. Northern Trust Corp now owns 421,810 shares of the company's stock worth $1,961,000 after purchasing an additional 50,256 shares in the last quarter. Oxford Asset Management LLP purchased a new stake in GoodRx in the fourth quarter valued at approximately $75,000. Finally, Two Sigma Securities LLC acquired a new stake in GoodRx during the 4th quarter worth $100,000. Hedge funds and other institutional investors own 63.77% of the company's stock.

GoodRx Stock Down 0.2%

GDRX stock traded down $0.01 during midday trading on Wednesday, reaching $4.53. The company had a trading volume of 1,610,204 shares, compared to its average volume of 1,386,247. The company has a market capitalization of $1.62 billion, a P/E ratio of -151.00, a PEG ratio of 2.46 and a beta of 1.16. GoodRx Holdings, Inc. has a 1 year low of $3.68 and a 1 year high of $9.26. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The company has a 50 day moving average of $4.25 and a two-hundred day moving average of $4.53.

GoodRx (NASDAQ:GDRX - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.09 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.04 by $0.05. GoodRx had a positive return on equity of 5.35% and a negative net margin of 2.05%. The firm had revenue of $202.97 million during the quarter, compared to analysts' expectations of $202.25 million. During the same quarter in the prior year, the business earned $0.08 earnings per share. The company's revenue was up 2.6% on a year-over-year basis. On average, equities research analysts expect that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current fiscal year.

Insider Activity

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the business's stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $4.09, for a total transaction of $43,668.93. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.53% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on GDRX shares. The Goldman Sachs Group dropped their price objective on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. Wells Fargo & Company cut their price target on GoodRx from $8.00 to $7.00 and set an "overweight" rating for the company in a research note on Tuesday, April 29th. UBS Group lowered their target price on GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. Finally, Truist Financial decreased their price target on shares of GoodRx from $6.50 to $5.50 and set a "hold" rating on the stock in a research note on Thursday, April 10th. Five research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, GoodRx currently has a consensus rating of "Moderate Buy" and a consensus price target of $6.55.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.